News Archive

IPO 40 times oversubscribed. 25% of stock are issued on the Mumbai Stock Exchange.

Dishman has achieved ISO 14001 and OHSAS 18001 certification of BVQI Switzerland

Dishman Europe Ltd receives the Queens Award for enterprise “International Trade”, one of Britain’s most prestigious awards for British companies

Dishman offers to undertake to fully fund new dedicated cGMP /US-FDA compliant facilities for individual clients where projects have an annual value of at least 5 Mio. USD and a contract period of at least 3 years.

Dishman’s manufacturing site in Bavla, India, has been granted the International Safety Award by the British Safety Council due to outstanding achievements w.r.t. its SHE Management System.

Dishman acquired IO3S of Bern Switzerland through its wholly owned subsidiary Dishman Switzerland Ltd. IO3S is the only company in the world in the field of consultancy and research in Ozone Chemistry. It has a fully developed laboratory as well as a pilot plant for Ozone based reactions. IO3S has created a strong IP, having serviced major global pharma companies and specialty chemical companies.

Dishman Pharmaceuticals and Chemicals Ltd (DPCL) announces that it has signed a Memorandum of Understanding (MoU) with Solvay Pharmaceuticals BV (Solvay), the Netherlands to acquire the fine chemicals, vitamin D and vitamin D analogues business from Solvay for an undisclosed amount. Read Press Release.

Dishman acquires the fine chemicals, vitamin D and Vitamin D analogues business from Solvay.

Inauguration of Unit 8 at Bavla Plant. This unit was inaugurated by Mr Jay R. Vyas and Mr Francisco Junyet (Solvay Pharmaceuticals) last 27 February 2008. This new facility has 4 floors dedicated to multi-products. See pictures of the inauguration.

The current production of Dishman Cholesterol and Lanoline products is sited in Veenendaal, a city in the centre of the Netherlands. Today, the supply of Vitamin D and Vitamin D analogues is still sited at the area of Solvay Pharmaceuticals. However, Dishman has recently decided to build a brand new facility for the Vitamin D Analogues in Veenendaal. The new facility will not only allow the production of the present Vitamin D Analogues, but also the development of new high potent products up to 1kg. This facility is expected to be ready in the course of 2009. From that moment the supply of Vitamin D and the Vitamin D Analogues will be concentrated in Veenendaal.

Dishman is building Asia’s largest facility to manufacture Cancer drugs and other high potency drugs at its Bavla plant. This facility is designed and being commissioned by its daughter company CARBOGEN AMCIS AG (CA) who has expertise in this area. Facility will be operated by CA’s Swiss team and it will product APIs for CARBOGEN AMICS AG to offer to its customers. Company has spent 50 crore rupees in building this facility.

Dishman is venturing in to manufacturing and marketing of disinfectant and sanitization products in India, Saudi Arabia and Australia. Company will make formulated products for hospitals, domestic use and industrial disinfection. In India and Australia, this will be done by company and its Australian subsidiary where as in Saudi, this will be under a JV called Dishman Arabia Ltd. with a Saudi partner. Company expect to reach 100 crore sales in 3 years from this new division.

Dishman is building Asia's largest facility to manufacture Cancer drugs and other high potency drugs at its Bavla plant. This facility is designed and being commissioned by its daughter company CARBOGEN AMCIS AG (CA) who has expertise in this area. Facility will be operated by CA's Swiss team and it will produce API's for CARBOGEN AMCIS AG to offer to its customers. Company has spent 50 crore rupees in building this facility.

(AHMEDABAD, INDIA), January 21, 2009 – Dishman Group of Ahmedabad, India, has announced capital investments of more than $33 million; $20 million in the current financial year and $13 million planned for fiscal year 2009 which begins in April. The global pharmaceutical services provider will see significant expansion of its capabilities and offerings this year, with the addition of a high-potency facility near Dishman’s headquarters in the district of Ahmedabad and a new plant in Shanghai, China.

The facility in India is a state-of-the-art, 4,300-square-meter plant catering to cytotoxic and non-cytotoxic highly active substances and one of the largest and most flexible custom-manufacturing high-potency facilities in the world. In Bavla, the plant will be managed and operated by Dishman subsidiary, Switzerland-based CARBOGEN AMCIS AG, and is scheduled to be operational mid-2009.

The facility in Shanghai will include a production plant, a warehouse, its own dedicated on-site utilities and administrative/quality control offices. Construction of the facility is fully underway and is expected to be fully staffed and operational by the second quarter of 2009.
“The new facilities in India and China will enable customers to solely collaborate with Dishman as a technical partner from early stage route development to market supply, without volume limitations. The addition of the plant in India offers customers a seamless approach to high-potency research and development, process optimization and commercial manufacturing,” said Jay Vyas, managing director of Dishman.
Dishman places a focus on safety and security, with an emphasis risk management strategy, which provides redundancy of supply in multiple Asian sites and countries and also provides ease of Asian collaboration. “Additional locations and infrastructure provide secure options that maximize speed, flexibility and cost advantages for customers with the same safety and quality standards globally,” said Vyas.

back   top   print